β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
Public ClinicalTrials.gov record NCT01470989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.
Study identification
- NCT ID
- NCT01470989
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2011 (Type not available)
- Primary completion
- May 2013 (Actual)
- Completion
- May 2013 (Actual)
- Last update posted
- Jul 9, 2021
2011 – 2013
United States locations
- U.S. sites
- 33
- U.S. states
- 16
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Anniston | Alabama | 36207-5710 | — |
| Novartis Investigative Site | Mobile | Alabama | 36608 | — |
| Novartis Investigative Site | Norwalk | California | 90650 | — |
| Novartis Investigative Site | Pasadena | California | 91105 | — |
| Novartis Investigative Site | San Diego | California | 92108 | — |
| Novartis Investigative Site | Tustin | California | 92780 | — |
| Novartis Investigative Site | Clearwater | Florida | 33756 | — |
| Novartis Investigative Site | Jupiter | Florida | 33458 | — |
| Novartis Investigative Site | Decatur | Georgia | 30035 | — |
| Novartis Investigative Site | Overland Park | Kansas | 66215 | — |
| Novartis Investigative Site | Topeka | Kansas | 66606 | — |
| Novartis Investigative Site | Wichita | Kansas | 67208 | — |
| Novartis Investigative Site | Metairie | Louisiana | 70006 | — |
| Novartis Investigative Site | Opelousas | Louisiana | 70570 | — |
| Novartis Investigative Site | Flint | Michigan | 48532 | — |
| Novartis Investigative Site | Troy | Michigan | 48085 | — |
| Novartis Investigative Site | Jackson | Mississippi | 39202 | — |
| Novartis Investigative Site | Jackson | Mississippi | 39209 | — |
| Novartis Investigative Site | Missoula | Montana | 59804 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68114 | — |
| Novartis Investigative Site | Freehold | New Jersey | 07728 | — |
| Novartis Investigative Site | Hickory | North Carolina | 28602 | — |
| Novartis Investigative Site | Dayton | Ohio | 45402 | — |
| Novartis Investigative Site | Willoughby Hills | Ohio | 44094 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29407 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29412 | — |
| Novartis Investigative Site | Columbia | South Carolina | 29204 | — |
| Novartis Investigative Site | Varnville | South Carolina | 29944 | — |
| Novartis Investigative Site | Bristol | Tennessee | 37620 | — |
| Novartis Investigative Site | Clarksville | Tennessee | 37043 | — |
| Novartis Investigative Site | Johnson City | Tennessee | 37601 | — |
| Novartis Investigative Site | Danville | Virginia | 24541 | — |
| Novartis Investigative Site | Newport News | Virginia | 23606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01470989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01470989 live on ClinicalTrials.gov.